Cabozantinib for liver cancer after prior treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug, cabozantinib, for people with liver cancer that has grown despite previous treatment with atezolizumab and bevacizumab. The goal is to see if this drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer that cannot be cured with surgery or other local treatments.
- You have already received atezolizumab and bevacizumab, and your cancer has progressed after that treatment.
- You are 18 years or older.
- You are generally able to care for yourself (ECOG performance status 0 or 1).
- Your liver function is good enough (Child-Pugh score A or B7).
- Your blood counts and kidney function meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
This study tests the drug cabozantinib (a pill that stops cancer growth) for people whose liver cancer has progressed after standard first-line immunotherapy. The goal is to see if it can slow down or shrink the cancer.
This trial studies cabozantinib, a cancer medicine, for liver cancer that has come back after a liver transplant. It’s for people whose cancer can’t be cured with more surgery or local procedures, to see if the treatment can help control the disease.
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.